← ANALYST RATINGS · TIPRANKS
Zentalis Pharmaceuticals (ZNTL): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $8.25, the highest $10.00, the lowest $5.00. The average is +287.3% from the last price of $2.13.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Sell | −6.1% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Sell | −6.1% | Downgrade | 15.10.26on TipRanks 16:05 | — | |
| Unknown Analyst | Leerink Partners | $4.00 → $8.00+100.0% | Buy | +275.6% | Upgrade | 05.10.26on TipRanks Oct 6 18:05 | +9.6%next day −4.5% · 5 days −9.8% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $5.00 | Hold | +134.7% | Reiterated | 29.09.26on TipRanks Sep 30 04:30 | +4.6%next day +2.2% · 5 days −3.6% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Initiated | 15.09.26on TipRanks 16:20 | −0.5%next day −1.8% · 5 days −9.5% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $8.00 | Buy | +275.6% | Reiterated | 11.08.26on TipRanks 07:50 | −0.6%next day +4.1% · 5 days −10.1% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $10.00 | Buy | +369.5% | Reiterated | 07.08.26on TipRanks Aug 10 07:35 | −16.2%next day −1.6% · 5 days −16.0% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $4.00 → $5.00+25.0% | Hold | +134.7% | Reiterated | 07.08.26on TipRanks 08:21 | −16.2%next day −1.6% · 5 days −16.0% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $10.00 | Buy | +369.5% | Reiterated | 07.08.26on TipRanks 07:06 | −16.2%next day −1.6% · 5 days −16.0% | ↗ |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $11.00 | Buy | +416.4% | Initiated | 23.07.26on TipRanks Jul 25 21:01 | +0.1%next day −2.8% · 5 days +10.1% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $9.00 | Buy | +322.5% | Initiated | 15.06.26on TipRanks 07:35 | −1.0%next day −6.3% · 5 days −0.1% | ↗ |
| Unknown Analyst | Wedbush | $4.00 | Hold | +87.8% | Reiterated | 13.05.26on TipRanks May 14 14:05 | −0.6%next day −5.2% · 5 days −13.2% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 12.05.26on TipRanks 18:35 | −0.6%next day −5.2% · 5 days −13.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Zentalis Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.17 at a price of $2.77 (+194.8%); now: $8.14 at $2.13 (+282.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 5 | 5 | 4 | 3 |
| Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.54 (from $-0.63 to $-0.42). Last quarter: $-0.59.
Best top-analyst consensus in the sector · Healthcare
About Zentalis Pharmaceuticals
- CEO: Julia Marie Eastland
- Employees: 106
- 10275 Science Center Drive, San Diego, CA, 92121, US
- www.zentalis.com
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Data from the stock’s TipRanks forecast page, read 71 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗